research use only

Colivelin Neuroprotective Peptide/STAT3 Activator

Name: Colivelin
Brand: Selleck Chemicals
SKU: S9664
Availability: InStock
Rating: 5 (15 reviews)

Cat.No.S9664

Colivelin (CLN) is a brain-penetrant neuroprotective peptide with potent long-term capacity against Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin is an activator of STAT3.

Chemical Structure

Molecular Weight: 2645.10

Jump to

Quality Control

Batch: S966401 DMSO]100 mg/mL]false]Water]100 mg/mL]false]]]false Purity: 99.62%

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

99.62

Related Targets	EGFR JAK Pim
Other STAT Inhibitors	Napabucasin (BBI608) Stattic NSC 74859 (S3I-201) Cryptotanshinone (Tanshinone C) C188-9 (TTI-101) SH-4-54 BP-1-102 AS1517499 Nifuroxazide HO-3867

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (37.8 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 100 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Clear solution	5% H2O 1 40% PEG 300 2 5% Tween 80 3 ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (1.89mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified H2O stock solution to 400 μL of PEG 300, mix evenly to clarify; add 50 μL of Tween 80 to the above system, mix evenly to clarify; Then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	2645.10	Formula	C₁₁₉H₂₀₆N₃₂O₃₅	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	867021-83-8	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	CLN			Smiles	CCC(C)C(C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(C(C)O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(C)NC(=O)CNC(=O)C(C)NC(=O)C2CCCN2C(=O)C(C)NC(=O)C3CCCN3C(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CO)N

Mechanism of Action

Targets/IC₅₀/Ki	Aβ STAT3
In vitro	Colivelin, a brain penetrant neuroprotective peptide, significantly increases the p-STAT3 protein levels in BV-2 cells.
In vivo	This compound protects against ischemic brain injury and improves neurological outcomes, by elevating anti-apoptotic genes up-regulation and activates JAK/STAT3 signaling afetr ischemic stroke.
References	[1] https://pubmed.ncbi.nlm.nih.gov/31374230/ [2] https://pubmed.ncbi.nlm.nih.gov/32098538/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04637282	Not yet recruiting	Juvenile Neuronal Ceroid Lipofuscinosis	Polaryx Therapeutics Inc.	December 1 2024	Phase 3
NCT05879744	Active not recruiting	NHL\|NHL Relapsed Adult	Cullinan Therapeutics Inc.	May 31 2023	Phase 1
NCT05143996	Recruiting	Relapsed/Refractory Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)	Cullinan Therapeutics Inc.	November 18 2021	Phase 1
NCT04974307	Completed	CLN3-related Disorders\|Low Vision	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|National Institutes of Health Clinical Center (CC)	September 30 2021	Not Applicable
NCT04480476	Withdrawn	Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)	REGENXBIO Inc.	March 31 2021	--
NCT04462692	Withdrawn	Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)	REGENXBIO Inc.	March 31 2021	--

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):